Sekita T, Tamaru J I, Isobe K, Harigaya K, Masuoka S, Katayama T, Kobayashi M, Mikata A
First Department of Pathology, School of Medicine, Chiba University, Japan.
Pathol Int. 1999 Aug;49(8):752-8. doi: 10.1046/j.1440-1827.1999.00929.x.
The expression of the natural killer (NK) cell antigen, CD56, in hematological malignancies is rare. However, there are several reports that some hematological malignancies, such as T/NK cell lymphoma, multiple myeloma (MM) and acute myeloid leukemia (AML), express this molecule. In B cell non-Hodgkin's lymphomas (NHL), however, very limited number of cases have been reported to express CD56 molecule. Although one study has recently described that half of microvillous B cell lymphoma (MVL), an uncommon subset of large cell lymphoma, expressed CD56, there have been no reports about most common type of B-NHL, diffuse large B cell lymphoma (DLBL) other than a mention of weak CD56 expression in one of 83 DLBL. We herein presented the first case of diffuse large B cell lymphoma expressing CD56 clearly. The immunophenotype determined by immunostaining and flow cytometric analysis was CD10+, CD19+, CD20+, CD45RO-, CD3- and CD56+. On immunohistochemical study, neither bcl-2 nor TIA-1 was positive for tumor cell. Monoclonal immunoglobulin heavy chain (IgH) gene rearrangement was detected, and the sequence analysis of the variable region of IgH (VH) suggested that this tumor was derived from antigen selected post germinal center B cell. Conventional combination chemotherapy (CHOP) was administered, and the patient has still been in complete remission for 10 months.
自然杀伤（NK）细胞抗原CD56在血液系统恶性肿瘤中的表达较为罕见。然而，有几份报告称，一些血液系统恶性肿瘤，如T/NK细胞淋巴瘤、多发性骨髓瘤（MM）和急性髓系白血病（AML），表达这种分子。然而，在B细胞非霍奇金淋巴瘤（NHL）中，据报道只有极少数病例表达CD56分子。尽管最近有一项研究描述，大细胞淋巴瘤的一个不常见亚型——微绒毛B细胞淋巴瘤（MVL）中有一半表达CD56，但除了在83例弥漫性大B细胞淋巴瘤（DLBL）中的1例中提到有弱CD56表达外，关于最常见的B-NHL类型——弥漫性大B细胞淋巴瘤，尚无相关报道。我们在此报告了首例明确表达CD56的弥漫性大B细胞淋巴瘤病例。通过免疫染色和流式细胞术分析确定的免疫表型为CD10+、CD19+、CD20+、CD�5RO-、CD3-和CD56+。免疫组织化学研究显示，肿瘤细胞中bcl-2和TIA-1均为阴性。检测到单克隆免疫球蛋白重链（IgH）基因重排，IgH可变区（VH）的序列分析表明，该肿瘤源自生发中心后B细胞经抗原选择产生的细胞。给予了常规联合化疗（CHOP），该患者至今已完全缓解10个月。
